riluzole has been researched along with Carcinoma, Renal Cell in 2 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with riluzole, a glutamate release inhibitor, has been previously shown to be safe in melanoma patients and produced biologic effects, but did not lead to radiographic responses, possibly due to poor pharmacokinetic properties." | 5.51 | A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. ( Berman, RM; Chan, N; Chen, S; Coric, V; Girda, E; Groisberg, R; Malhotra, J; Mehnert, JM; Palmeri, M; Saraiya, B; Saunders, T; Shih, W; Silk, AW; Spencer, K; Vieth, J; Zloza, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silk, AW | 1 |
| Saraiya, B | 1 |
| Groisberg, R | 1 |
| Chan, N | 1 |
| Spencer, K | 1 |
| Girda, E | 1 |
| Shih, W | 1 |
| Palmeri, M | 1 |
| Saunders, T | 1 |
| Berman, RM | 1 |
| Coric, V | 1 |
| Chen, S | 2 |
| Zloza, A | 1 |
| Vieth, J | 1 |
| Mehnert, JM | 1 |
| Malhotra, J | 1 |
| Martino, JJ | 1 |
| Wall, BA | 1 |
| Mastrantoni, E | 1 |
| Wilimczyk, BJ | 1 |
| La Cava, SN | 1 |
| Degenhardt, K | 1 |
| White, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies[NCT03229278] | Phase 1 | 14 participants (Actual) | Interventional | 2017-10-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MTD of trigriluzole in combination with nivolumab will be identified. The MTD will then be tested in combination with pembrolizumab using the same escalate/de-escalate/stay rules. Data on the adverse event type, severity and frequency will be recorded. (NCT03229278)
Timeframe: Four weeks
| Intervention | mg (Number) |
|---|---|
| All Participants | 420 |
A DLT was any Grade 3 or 4 adverse event (AE) using the Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE 3.0) that was possibly Trigriluzole or Nivolumab related. CTCAE 3.0 Grade 3 is a severe AE and Grade 4 is a life- threatening or disabling AE. DLTs were collected to determine the Maximum-Tolerated Dose (MTD), which is defined as the dose level below the dose at which 33% of participants experienced a DLT. (NCT03229278)
Timeframe: Four weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 140 mg Taken by Mouth Daily (PO) | 0 |
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 140 mg PO Twice a Day (BID) | 0 |
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 140 mg /280mg | 1 |
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 280mg PO BID | 2 |
Continuous variables will be presented by summary statistics (such as mean, median, standard error and 95% confidence intervals [CI]) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 95% CI). (NCT03229278)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 280mg PO BID | 7 |
1 trial available for riluzole and Carcinoma, Renal Cell
| Article | Year |
|---|---|
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Topics: Bayes Theorem; Carcinoma, Renal Cell; Enzyme Inhibitors; Glutamates; Humans; Kidney Neoplasms; Melan | 2022 |
1 other study available for riluzole and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplasti | 2013 |